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Abstract 
 
Objective: To investigate whether low-density granulocytes (LDGs) are a immunophenotypic 
feature of patients with multiple sclerosis (MS) and/or neuromyelitis optica spectrum disorder 
(NMOSD). 
 
Methods: Blood samples were collected from 26 patients with NMOSD and 20 patients with MS, 
as well as from 18 patients with Systemic Lupus Erythematosus (SLE) and 23 Healthy Donors 
(HD). We isolated peripheral blood mononuclear cells (PBMCs) with density gradient separation 
and stained the cells with antibodies against CD14, CD15, CD16, and CD45, and analysed the cells 
by flow cytometry or imaging flow cytometry. We defined LDGs as CD14-CD15high and calculated 
their share in total PBMC leukocytes (CD45+) as well as the share of CD16hi LDGs. Clinical data on 
disease course, medication, and antibody status were obtained.  
 
Results: LDGs were significantly more common in MS and NMOSD than in HDs, comparable to 
SLE samples (median values HD 0.2%, MS 0.9%, NMOSD 2.1%, SLE 4.3%). 0/23 of the HDs, but 
17/20 NMOSD and 11/17 MS samples as well as 13/15 SLE samples had at least 0.7 % LDGs. 
NMOSD patients without continuous immunosuppressive treatment had significantly more LDGs 
compared to their treated counterparts. LDG nuclear morphology ranged from segmented to 
rounded, suggesting a heterogeneity within the group. 
 
Conclusion: LDGs are a feature of the immunophenotype in some patients with MS and NMOSD.  
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Background 
Low-Density Granulocytes (LDGs) are neutrophilic granulocytes that remain in the fraction of 
peripheral blood mononuclear cells (PBMC) after density gradient separation. When first described, 
they were noted to be a feature of rheumatologic diseases such as Systemic Lupus Erythematosus 
(SLE) (1), while more recent works described LDGs in various conditions such as asthma (2), 
tuberculosis (3), and psoriasis (4). LDGs have been implicated in the pathogenesis of SLE by 
producing type I interferons and undergoing spontaneous NETosis (generation of Neutrophil 
extracellular traps), thus providing potentially immunogenic nuclear matter (5,6). Their role in the 
pathogenesis of other diseases is less clear. 
 
The origin of the LDGs is not yet explained and it has been proposed that they represent immature 
or degranulated neutrophils. Interestingly, LDGs in SLE display an immature nuclear structure even 
though they express the surface markers of mature granulocytes, such as CD16. (5,6) 
 
Neuromyelitis Optica Spectrum Disorder (NMOSD) and Multiple Sclerosis (MS) are 
neuroinflammatory conditions of unknown etiology. The evidence for the involvement of 
granulocytes in the pathogenesis of MS has been scarce so far, while some early studies indicate a 
role of neutrophils in NMOSD pathogenesis. (7,8) 
 
In this study, we provide the first evidence for the existence of LDGs in MS and NMOSD and thus 
add another puzzle piece to the role of the innate immune system in the pathogenesis of these 
diseases. 
 
Methods 
 
Patient selection 
SLE patients were recruited from the rheumatologic outpatient departments at Charité 
Universitätsmedizin Berlin. Data on MS- and NMOSD-patients were derived from ongoing 
observational studies at the NeuroCure Clinical Research Center, Charité – Universitätsmedizin 
Berlin. These studies were approved by the ethics committee of the Charité – Universitätsmedizin 
Berlin (MS: EA1/163/12; NMOSD: EA1/041/14) and conducted according to the 1964 Declaration 
of Helsinki in its currently applicable version. Written, informed consent was obtained from all 
participants in the study. 
MS-diagnosis was made according to the 2010 revised McDonald criteria, NMOSD-diagnosis was 
made according to the international consensus diagnostic criteria for NMOSD 2015. 
All MS and NMOSD patients were a stable phase of disease with a minimum of three months since 
the last relapse and last glucocorticoid pulse. We excluded patients if they received the diagnosis of 
an additional autoimmune, infectious or malignant condition. We correlated the LDG percentage 
with clinical information such as Expanded Disability Status Scale (EDSS) score, number of 
relapses, treatment, and duration of disease as well as titres for anti-MOG and anti-AQP4 
antibodies. 
 
PBMS isolation, Staining and Flow Cytometry 
We isolated the PBMC layer with density-gradient separation of 10ml heparin-anticoagulated 
blood, using the Ficoll-Paque PLUS gradient (GE Healthcare). PBMCs were washed once in 
phosphate-buffered saline (PBS) supplemented with 3% bovine serum albumin (BSA) and 
subsequently stained with the following antibody-conjugates: CD45 FITC (clone 5B1, Miltenyi), 
CD14 Cy5 (clone TM1, DRFZ), CD15 PE-Cy7 (clone W6D3, Biolegend), CD16 PE (clone 3G8, 
Biolegend), CD14 APC-Cy7 (clone 63D3, Biolegend) and CD11c Pacific Blue (clone M1/70, 
Biolegend). We acquired the sample using a FACSCanto (BD Biosciences) or MACSQuant 
(Miltenyi) cytometer. For imaging flow cytometry (Amnis), we isolated and stained the cells as 
described above, fixed the sample with the Foxp3 / Transcription Factor Staining Buffer Set 
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(eBioscience) and acquired the cells on an Amnis ImageStream X Mark II. All cytometry 
experiments were performed in accordance with the “Guidelines for the use of flow cytometry and 
cell sorting in immunological studies”. (9) 
 
FACS Data Analysis 
We excluded sub-cell-sized detritus and doublets based on scatter characteristics and gated on 
CD45+ leukocytes. Of these, we defined LDGs as CD14-CD15high and calculated the ratio of LDGs 
of all CD45+ PBMCs (Fig 1a). We then determined the fraction of CD16high LDGs. FACS Data 
Analysis was performed using FlowJo Version 10.4.1 (FlowJo LLC). We analyzed the 
ImageStream data with IDEAS Version 6.2 (Amnis). 
 
Statistical Analysis 
The percentage of LDGs of different disease states and the percentage of CD16high LDGs were 
compared to HDs using the Kruskal-Wallis test with Dunn’s Correction for multiple testing. For the 
difference between two groups, we used the Mann-Whitney test. All statistical analysis was 
performed in GraphPad Prism Version 7.0e for Mac OS X (GraphPad Software). 
 
Results 
 
LDGs are a feature of many inflammatory conditions and of unknown pathogenic significance. To 
elucidate whether LDGs also exist in NMOSD and MS, we performed FACS analyses of 76 
peripheral blood samples.   
 
Cohort Description 
We conducted the analysis of 17 MS patients as well as 20 patients with NMOSD. 15 patients with 
SLE and 23 HDs served as controls. Median EDSS scores were 4.0 in the MS and 3.0 in the 
NMOSD group. The most common treatments in the MS group were Dimethylfumarate (6/17) and 
beta Interferon (4/17). The median number of relapses in the relapse-remitting MS (RRMS) patients 
was 2.5. NMOSD Patients were most often treated with Rituximab (8/20), Mycophenolate (4/20) 
and Azathioprine (4/20). (Table 1) 
 
Low-Density Granulocytes are a feature of both multiple sclerosis and neuromyelitis optica  
In comparison to healthy controls, both MS and NMO patients feature a significantly higher 
percentage of LDGs. SLE samples displayed the highest frequencies of LDGs. (MS: 0.9%, NMO 
2.1%, SLE: 4.3%, HD: 0.2%, median fraction of CD45+ cells) (Fig 1a). None of the HDs, but 17/20 
NMOSD and 11/17 MS samples as well as 13/15 SLE samples had at least 0.7 % LDGs. The 
fraction of CD16high LDGs differed both between and within groups (Fig 1b), but was significantly 
higher in NMOSD and MS compared to HCs. LDGs uniformly expressed CD11b (Fig 1c). 
 
LDGs show a heterogeneous nuclear morphology 
We analyzed the nuclear morphology of the LDGs of a NMO patient. While some of the CD14-, 
CD15high cells displayed the segmented nuclear shape typical of mature granulocytes, others showed 
band-formed or rounded nuclei, which are traditionally thought to be immature forms. (Fig 2) 
 
Untreated NMOSD patients show higher LDG fractions 
We looked for associations between the fraction of LDGs in MS and NMO patients and their 
clinical characteristics such as time since first manifestation of disease, number of relapses, severity 
of disability as judged by the EDSS score, type of treatment and antibody status, but did not find 
any significant correlations. (Data not shown) NMOSD patients who did not receive a continuous 
immunosuppressive treatment had significantly higher LDG percentages compared to their peers 
receiving treatment. (median LDGs treated 1.4% untreated 7.9%, p < 0.01). The LDG fraction did 
not correlate with clinical severity.  
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 Discussion 
This study demonstrates the presence of LDGs in MS and NMOSD. In contrast to MS, in NMO 
classical granulocytes are thought to play a pivotal role as they can be found in tissue biopsies (7) 
and alterations in neutrophil function have been described (8). We recently described CD11b+ 
leucocytes in the PBMCs of MS patients that were characterized by increased activation of 
NAD(P)H oxidase (NOX). (10) In these, NOX activation correlated with clinical activity. While we 
assumed these cells to be monocytes at the time, the presence of LDGs in the peripheral blood 
mononuclear cell (PBMC) fraction could pose an alternative explanation for our previous results. 
 
We found the LDG fraction of NMOSD and MS patients to contain significantly more CD16high 
cells, a marker indicating neutrophil maturity. As previously described for LDGs in SLE, LDG 
nuclei in NMOSD vary between mature segmented and immature round forms. In previous studies, 
the immature nuclear morphology was associated with a expression of surface markers 
characteristic of mature cells, suggesting that LDGs do not fit into the traditional maturity spectrum 
of granulocytes. (6) 
 
This work adds MS and NMOSD to the diverse list of inflammatory conditions featuring LDGs. In 
our opinion, this makes it more likely that LDGs are an epiphenomenon of ongoing inflammation 
rather than a causal part of the pathogenesis of a specific disease, but further research is needed to 
establish the role of these cells in different conditions.  
 
To establish the potential of LDGs as a biomarker in neuroinflammatory diseases or inflammation 
in general, analysis of larger and longitudinal cohorts should be performed to uncover potential 
correlations with disease severity or prognosis.  
 
 
Tables:  
 
Table 1: Epidemiological Information of the Study Population 
 
 NMOSD (n = 20) MS (n = 17) HD (n = 23) SLE (n = 15) 
Age (median and 
interquartile range) 
48 (34.0 – 56.5) 47 (36.0 – 51.0) 29 (27.0 – 
43.5) 
40 (31.0 –
48.0) 
Sex (n and percentage 
female) 
17 (85.0) 5 (29.4) 15 (65.2) 14 (93.3) 
Time since disease 
onset (in years, 
median and 
interquartile range) 
7.0 (3.0 – 8.8) 9.7 (4.6 – 15.4) – n.d. 
Time since last 
relapse (in years, 
median and 
interquartile range) 
n.d. 3.4 (1.5 – 8.3) – n.d. 
Clinical severity 
(EDSS for MS and 
NMO, SLEDAI for 
SLE median and 
interquartile range)  
3 (1.5 – 4.5) 4 (2.0 –5.0) – 5 (2.0 – 7.0) 
Treatments (n, 
percentage) 
Rituximab n=8 
(40.0), Azathioprine 
and untreated each 
Dimethylfumarat 
n=6 (35.3), 
Interferon beta 
– n.d. 
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n=4 (20.0), 
Mycophenolate n=3 
(15.0), 
Teriflunomide n=1 
(5.0) 
n=4 (23.4),  
untreated n=3 
(17.6), 
Daclizumab, 
intrathecal 
Steroids, 
Glatirameracetate 
and Fingolimod 
each n=1 (5.9) 
Autoantibody Status 
(n, percentage) 
AQP-4 n=8 (40.0) 
MOG n=4 (20.0) 
– – – 
% of LDGs (median 
and interquartile 
range) 
2.1 (1.1 – 4.1) 0.9 (0.57 – 1.63) 0.2 (0.2 – 0.4) 4.3 (1.0 – 9.5) 
% of CD16high LDGs 
(median and 
interquartile range) 
91.2 (77.2 – 94.9) 87.8 (67.3 – 
94.4) 
65.6 (53.7 – 
79.9) 
84.6 (64.6 – 
89.6) 
 
 
Figures  
 
Figure 1 
 
a) LDGs (CD14-CD15high) are a feature NMOSD and MS but not HDs (HD: n = 23, NMOSD: n = 
20, MS: n = 17 SLE: n = 15). Bars indicate median and 95% Confidence Intervals. The horizontal 
bar indicates 0.7%, a cut-off that seperates all HDs from 17/20 NMOSD, 11/17 MS samples as well 
as 13/15 SLE. Kruskal-Wallis test with Dunn’s Correction for multiple testing **: p < 0.005, ****: 
p < 0.0001) 
b) Most LDGs are CD16high, but there are more CD16high LDGs in NMO and MS than in HDs. 
There are some outliers with very low levels of CD16high LDGs. Bars indicate median and 95% 
Confidence Intervals. Kruskal-Wallis test with Dunn’s Correction for multiple testing.  (HD: n = 23, 
NMOSD: n = 20, MS: n = 16 SLE: n = 15), Test, *: p < 0.05, ***: p < 0.001) 
c) LDGs are CD11b+ (Gated on CD14-CD15+, gray: fluorescence minus one (FMO) control) 
 
 
Figure 2: 
Imaging flow cytometry analysis of LDGs from a patient with NMO revealed heterogenous nuclear 
shapes, ranging from round to multisegmented.  
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